Compare Recursion Pharmaceuticals Inc (RXRX) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Star Bulk Carriers Corp trades at $26.59 (market cap $2.91B). The key difference: Star Bulk Carriers Corp is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 3.95% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SBLK | |
|---|---|---|
Market Cap | $1.53B | $2.91B |
Sector | Health | Industrials |
52-Week High | $6.79 | $28.21 |
52-Week Low | $2.84 | $16.79 |
Enterprise Value | $946.50M | $3.61B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Star Bulk Carriers (SBLK) trades at $26.09, up 4.78% in the last session, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in Q4 2025 and Q1 2026, with Q2 2026 EPS expected at $0.96. Financials show improving profitability, with a net income margin of 13.01% in 2026, and a dividend of $0.50 paid in June 2026. Analyst consensus is bullish, with 14 buys out of 24 ratings.
SBLK's outlook is supported by robust free cash flow and a healthier balance sheet, but risks include spot rate volatility and broader market pressures. The stock offers potential for high dividend yields and earnings growth, though investor caution is warranted amid sector cyclicality and economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
